Role of bacterial endotoxin in chronic heart failure: The gut of the matter

Shock

Volumn 28, Issue 1, 2007, Pages 15-23

  Charalambous, Bambos M ^a,d   Stephens, Robert C M ^b   Feavers, Ian M ^c   Montgomery, H E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antibodies; E. coli; Endotoxin; Hypoxia; Inflammation; Interleukins; Nitric oxide; Pathology

Indexed keywords

BACTERIAL VACCINE; BACTERIUM LIPOPOLYSACCHARIDE; CENTOXIN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; ENDOTOXIN; ENDOTOXIN ANTIBODY; ESCHERICHIA COLI VACCINE; GELATINASE A; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID A; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E5; MONOCYTE CHEMOTACTIC PROTEIN 1; OLIGOSACCHARIDE; SALMONELLA TYPHIMURIUM VACCINE; SHIGELLA VACCINE; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIBRIO CHOLERA VACCINE;

ACUTE CORONARY SYNDROME; DISEASE SEVERITY; GASTROINTESTINAL TRACT; GRAM NEGATIVE BACTERIUM; HEART FAILURE; HUMAN; HYPOXEMIA; IMMUNOTHERAPY; INFLAMMATION; MONOCYTE; MOUSE STRAIN; NONHUMAN; RABBIT; REVIEW; SEPSIS; T LYMPHOCYTE; UNSTABLE ANGINA PECTORIS;

CYTOKINES; DIGESTIVE SYSTEM; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MODELS, BIOLOGICAL; MONOCYTES;

EID: 34250768216     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/shk.0b013e318033ebc5     Document Type: Review

References (187)

1. Niebauer J, Volk HD, Kemp M, et al.: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353:1838-1842, 1999.
2. Anker SD, Egerer KR, Volk HD, et al.: Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79:1426-1430, 1997.
3. Yang RB, Mark MR, Gray A, et al.: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 395:284-288, 1998.
4. O'Dwyer ST, Michie HR, Ziegler TR, et al.: A single dose of endotoxin increases intestinal permeability in healthy humans. Arch Surg 123:1459-1464, 1988.
5. Salzman AL, Wang H, Wollert PS, et al.: Endotoxin-induced ileal mucosal hyperpermeability in pigs: role of tissue acidosis. Am J Physiol 266:G633-G646, 1994.
6. Ding J, Magnotti LJ, Huang Q, et al.: Hypoxia combined with Escherichia coli produces irreversible gut mucosal injury characterized by increased intestinal cytokine production and DNA degradation. Shock 16:189-195, 2001.
7. Lobo SM, De Backer D, Sun Q, et al.: Gut mucosal damage during endotoxic shock is due to mechanisms other than gut ischemia. J Appl Physiol 95:2047-2054, 2003.
8. Aukrust P, Yndestad A, Ueland T, et al.: Anti-inflammatory trials in chronic heart failure. Heart Fail Monit 5:2-9, 2006.
9. Aukrust P, Yndestad A, Ueland T, et al.: The role of intravenous immunoglobulin in the treatment of chronic heart failure. Int J Cardiol 112:40-45, 2006.
10. Sharma R, Bolger AP, Rauchhaus M, et al.: Cellular endotoxin desensitization in patients with severe chronic heart failure. Eur J Heart Fail 7:865-868, 2005.
11. Kruger S, Kunz D, Graf J, et al.: Endotoxin hypersensitivity in chronic heart failure. Int J Cardiol 115:159-163, 2007.
12. Conraads VM, Jorens PG, De Clerck LS, et al.: Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail 6:483-491, 2004.
13. Martinez-Pellus AE, Merino P, Bru M, et al.: Endogenous endotoxemia of intestinal origin during cardiopulmonary bypass. Role of type of flow and protective effect of selective digestive decontamination. Intensive Care Med 23:1251-1257, 1997.
14. Fox MA, Peterson S, Fabri BM, et al.: Selective decontamination of the digestive tract in cardiac surgical patients. Crit Care Med 19:1486-1490, 1991.
15. Anker SD, von Haehling S: Inflammatory mediators in chronic heart failure: an overview. Heart 90:464-470, 2004.
16. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454, 1999.
17. Levine B, Kalman J, Mayer L, et al.: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236-241, 1990.
18. Blum A, Sclarovsky S, Rehavia E, et al.: Levels of T-lymphocyte subpopulations, interleukin-1 beta, and soluble interleukin-2 receptor in acute myocardial infarction. Am Heart J 127:1226-1230, 1994.
19. Rauchhaus M, Doehner W, Francis DP, et al.: Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102:3060-3067, 2000.
20. Kumar A, Haery C, Parrillo JE: Myocardial dysfunction in septic shock. Crit Care Clin 16:251-287, 2000.
21. Kumar A, Brar R, Wang P, et al.: Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 276:R265-R276, 1999.
22. Nakanishi K, Takeda S, Terajima K, et al.: Myocardial dysfunction associated with proinflammatory cytokines after esophageal resection. Anesth Analg 91:270-275, 2000.
23. Cain BS, Meldrum DR, Dinarello CA, et al.: Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 27:1309-1318, 1999.
24. Kraut EJ, Chen S, Hubbard NE, et al.: Tumor necrosis factor depresses myocardial contractility in endotoxemic swine. J Trauma 46:900-906, 1999.
25. Parker MM: Pathophysiology of cardiovascular dysfunction in septic shock. New Horiz 6:130-138, 1998.
26. Oddis CV, Finkel MS: Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes. Biochem Biophys Res Commun 213:1002-1009, 1995.
27. Mayers I, Hurst T, Puttagunta L, et al.: Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts. J Thorac Cardiovasc Surg 122:746-752, 2001.
28. Kumar A, Kumar A, Parrillo JE: Cytokines and septic myocardial depression: nitric oxide versus sphingosine/ceramide? Crit Care Med 27:1391-1393, 1999.
29. Haque R, Kan H, Finkel MS: Effects of cytokines and nitric oxide on myocardial E-C coupling. Basic Res Cardiol 93(suppl 1):86-94, 1998.
30. Laycock SK, Vogel T, Forfia PR, et al.: Role of nitric oxide in the control of renal oxygen consumption and the regulation of chemical work in the kidney. Circ Res 82:1263-1271, 1998.
31. Loke KE, Laycock SK, Mital S, et al.: Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation 100:1291-1297, 1999.
32. Loke KE, McConnell PI, Tuzman JM, et al.: Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res 84:840-845, 1999.
33. Shen W, Wolin MS, Hintze TH: Defective endogenous nitric oxide-mediated modulation of cellular respiration in canine skeletal muscle after the development of heart failure. J Heart Lung Transplant 16:1026-1034, 1997.
34. Wolin MS, Hintze TH, Shen W, et al.: Involvement of reactive oxygen and nitrogen species in signalling mechanisms that control tissue respiration in muscle. Biochem Soc Trans 25:934-939, 1997.
35. Zhang X, Xie YW, Nasjletti A, et al.: ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 95:176-182, 1997.
36. Zhao G, Bernstein RD, Hintze TH: Nitric oxide and oxygen utilization: exercise, heart failure and diabetes. Coron Artery Dis 10:315-320, 1999.
37. Wagenmakers AJ: Muscle function in critically ill patients. Clin Nutr 20:451-454, 2001.
38. Rosenbloom AJ, Pinsky MR, Bryant JL, et al.: Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 274:58-65, 1995.
39. Marshall JC: Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29:S99-S106, 2001.
40. Finkel MS, Oddis CV, Jacob TD, et al.: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257:387-389, 1992.
41. Oddis CV, Finkel MS: Cytokines and nitric oxide synthase inhibitor as mediators of adrenergic refractoriness in cardiac myocytes. Eur J Pharmacol 320:167-174, 1997.
42. Torre-Amione G, Kapadia S, Benedict C, et al.: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201-1206, 1996.
43. Habib FM, Springall DR, Davies GJ, et al.: Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 347:1151-1155, 1996.
44. Kapadia SR, Oral H, Lee J, et al.: Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 81:187-195, 1997.
45. Valgimigli M, Merli E, Malagutti P, et al.: Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol 43:2000-2008, 2004.
46. Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, et al.: Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes. Coron Artery Dis 14:431-438, 2003.
47. Jolda-Mydlowska B, Salomon P: Cytokines and remodelling of the heart in patients with congestive heart failure. Pol Arch Med Wewn 109:23-33, 2003.
48. Geppert A, Steiner A, Zorn G, et al.: Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 30:1987-1994, 2002.
49. Oral H, Dorn GW, Mann DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem 272:4836-4842, 1997.
50. Favory R, Lancel S, Marchetti P, et al.: Endotoxin-induced myocardial dysfunction: evidence for a role of sphingosine production. Crit Care Med 32:495-501, 2004.
51. Muller-Werdan U, Engelmann H, Werdan K: Cardiodepression by tumor necrosis factor-alpha. Eur Cytokine Netw 9:689-691, 1998.
52. Gao CQ, Sawicki G, Suarez-Pinzon WL, et al.: Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 57:426-433, 2003.
53. Adams V, Jiang H, Yu J, et al.: Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 33:959-965, 1999.
54. Ferrari R, Bachetti T, Confortini R, et al.: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92:1479-1486, 1995.
55. Deswal A, Petersen NJ, Feldman AM, et al.: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103:2055-2059, 2001.
56. Sharma R, Bolger AP, Li W, et al.: Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 92:188-193, 2003.
57. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91:988-998, 2002.
58. Bolger AP, Anker SD: Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 60:1245-1257, 2000.
59. von Haehling S, Jankowska EA, Anker SD: Tumour necrosis factor-alpha and the failing heart-pathophysiology and therapeutic implications. Basic Res Cardiol 99:18-28, 2004.
60. Cicoira M, Bolger AP, Doehner W, et al.: High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine 15:80-86, 2001.
61. Nieman DC: Immune response to heavy exertion. J Appl Physiol 82:1385-1394, 1997.
62. Jansky L, Pospisilova D, Honzova S, et al.: Immune system of cold-exposed and cold-adapted humans. Eur J Appl Physiol Occup Physiol 72:445-450, 1996.
63. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 265:621-636, 1990.
64. Mohamed-Ali V, Flower L, Sethi J, et al.: beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 86:5864-5869, 2001.
65. Castell JV, Gomez-Lechon MJ, David M, et al.: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 242:237-239, 1989.
66. Castell JV, Gomez-Lechon MJ, David M, et al.: Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12:1179-1186, 1990.
67. Dalmon J, Laurent M, Courtois G: The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 13:1183-1193, 1993.
68. Kishimoto T: The biology of interleukin-6. Blood 74:1-10, 1989.
69. Wollert KC, Drexler H: The role of interleukin-6 in the failing heart. Heart Fail Rev 6:95-103, 2001.
70. Raymond RJ, Dehmer GJ, Theoharides TC, et al.: Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 141:435-438, 2001.
71. Munger MA, Johnson B, Amber IJ, et al.: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 77:723-727, 1996.
72. Aukrust P, Ueland T, Lien E, et al.: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83:376-382, 1999.
73. Carlstedt F, Lind L, Lindahl B: Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease. J Intern Med 242:361-365, 1997.
74. Roig E, Orus J, Pare C, et al.: Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 82:688-690, 1998. A8.
75. Tsutamoto T, Hisanaga T, Wada A, et al.: Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31:391-398, 1998.
76. Orus J, Roig E, Perez-Villa F, et al.: Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant 19:419-425, 2000.
77. Hjalmarson A, Fagerberg B: MERIT-HF mortality and morbidity data. Basic Res Cardiol 95(suppl 1):I98-I103, 2000.
78. Gullestad L, Ueland T, Brunsvig A, et al.: Effect of metoprolol on cytokine levels in chronic heart failure-a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J 141:418-421, 2001.
79. Gullestad L, Kjekshus J, Damas JK, et al.: Agents targeting inflammation in heart failure. Expert Opin Investig Drugs 14:557-566, 2005.
80. Gullestad L, Aukrust P: Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 95:17C-23C, 2005.
81. Brunkhorst FM: Endotoxins in chronic heart failure. Lancet 354:599-600, 1999.
82. Rauchhaus M, Koloczek V, Volk H, et al.: Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 76:125-133, 2000.
83. Wilson M: Microbial Inhabitants of Humans; Their Ecology and Role in Health and Disease. Cambridge, NY: Cambridge University Press, 2005.
84. Simon GL, Gorbach SL: The human intestinal microflora. Dig Dis Sci 31:147S-162S, 1986.
85. Simon GL, Gorbach SL: Intestinal flora in health and disease. Gastroenterology 86:174-193, 1984.
86. Moran AP: Structure-bioactivity relationships of bacterial endotoxins. J Toxicol Toxin Rev 14:47-83, 1994.
87. Rietschel ET, Brade L, Holst O, et al.: Molecular structure of bacterial endotoxin in relation to bioactivity. In: Nowotny A, Spitzer JJ, Ziegler EJ (eds.): Endotoxin Research Series, Vol 1. Amsterdam, The Netherlands: Elsevier Science Publishers B.V., pp 15-32, 1990.
88. Genth-Zotz S, von Haehling S, Bolger AP, et al.: Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 90:1226-1230, 2002.
89. van Deventer SJ, Buller HR, ten Cate JW, et al.: Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520-2526, 1990.
90. Le Contel C, Vinit MA, Parant FJ, et al.: Differential priming for endotoxin-induced circulating cytokine production by tumor necrosis factor-alpha and interleukin 1 beta. Cytokine 2:375-380, 1990.
91. Cicco NA, Lindemann A, Content J, et al.: Inducible production of interleukin-6 by human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha. Blood 75:2049-2052, 1990.
92. Bailly S, Ferrua B, Fay M, et al.: Differential regulation of IL 6, IL 1 A, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role of cyclic AMP. Cytokine 2:205-210, 1990.
93. Andersson U, Matsuda T: Human interleukin 6 and tumor necrosis factor alpha production studied at a single-cell level. Eur J Immunol 19:1157-1160, 1989.
94. Libermann TA, Baltimore D: Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327-2334, 1990.
95. Oyama J, Blais C Jr, Liu X, et al.: Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109:784-789, 2004.
96. Poltorak A, He X, Smirnova I, et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088, 1998.
97. Lien E, Means TK, Heine H, et al.: Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 105: 497-504, 2000.
98. Smiley ST, King JA, Hancock WW: Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 167:2887-2894, 2001.
99. Miller YI, Viriyakosol S, Binder CJ, et al.: Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 278:1561-1568, 2003.
100. Ohashi K, Burkart V, Flohe S, et al.: Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164:558-561, 2000.
101. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394-397, 1997.
102. Schnare M, Barton GM, Holt AC, et al.: Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2:947-950, 2001.
103. Liuzzo G, Angiolillo DJ, Buffon A, et al.: Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation 103:2236-2241, 2001.
104. Hollestelle SC, De Vries MR, Van Keulen JK, et al.: Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109:393-398, 2004.
105. Methe H, Kim JO, Kofler S, et al.: Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 111:2654-2661, 2005.
106. Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol 2:108-115, 2001.
107. Moser B, Loetscher P: Lymphocyte traffic control by chemokines. Nat Immunol 2:123-128, 2001.
108. Strieter RM, Polverini PJ, Arenberg DA, et al.: Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 57:752-762, 1995.
109. Frangogiannis NG: Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 13:1877-1893, 2006.
110. Carter AM: Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2:113-121, 2005.
111. Kitchens RL, Thompson PA: Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 11:225-229, 2005.
112. Heumann D, Roger T: Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta 323:59-72, 2002.
113. Wright SD: CD14 and innate recognition of bacteria. J Immunol 155:6-8, 1995.
114. Ulevitch RJ, Tobias PS: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13:437-457, 1995.
115. Gioannini TL, Zhang D, Teghanemt A, et al.: An essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD14 and resultant cell activation. J Biol Chem 277:47818-47825, 2002.
116. Shands JW Jr, Chun PW: The dispersion of gram-negative lipopolysaccharide by deoxycholate. Subunit molecular weight. J Biol Chem 255:1221-1226, 1980.
117. Brogden KA, Phillips M: The ultrastructural morphology of endotoxins and lipopolysaccharides. Electron Microsc Rev 1:261-278, 1988.
118. Wright SD, Ramos RA, Tobias PS, et al.: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433, 1990.
119. Hailman E, Lichenstein HS, Wurfel MM, et al.: Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 179:269-277, 1994.
120. Deleted in proof.
121. Takeuchi O, Hoshino K, Kawai T, et al.: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443-451, 1999.
122. Shimazu R, Akashi S, Ogata H, et al.: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189:1777-1782, 1999.
123. Tobias PS, Soldau K, Ulevitch RJ: Isolation of a lipopolysaccharide- binding acute phase reactant from rabbit serum. J Exp Med 164:777-793, 1986.
124. Triantafilou M, Triantafilou K: Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23:301-304, 2002.
125. Wurfel MM, Kunitake ST, Lichenstein H, et al.: Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 180:1025-1035, 1994.
126. Wurfel MM, Hailman E, Wright SD: Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 181:1743-1754, 1995.
127. Gazzano-Santoro H, Meszaros K, Birr C, et al.: Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 62:1185-1191, 1994.
128. Elsbach P, Weiss J: The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide. Immunobiology 187:417-429, 1993.
129. Tobias PS, Soldau K, Iovine NM, et al.: Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS. J Biol Chem 272:18682-18685, 1997.
130. Cohn JN: The management of chronic heart failure. N Engl J Med 335:490-498, 1996.
131. Grum CM: Tissue oxygenation in low flow states and during hypoxemia. Crit Care Med 21:44-49, 1993.
132. David H, Siems WG, Ellermann J: Ultrastructure and biochemistry of ischemic damages of small intestinal epithelial cells. Exp Toxicol Pathol 44:325-335, 1992.
133. Parks DA, Granger DN: Contributions of ischemia and reperfusion to mucosal lesion formation. Am J Physiol 250:G749-G753, 1986.
134. Noda T, Iwakiri R, Fujimoto K, et al.: Programmed cell death induced by ischemia-reperfusion in rat intestinal mucosa. Am J Physiol 274:G270-G276, 1998.
135. Ikeda H, Suzuki Y, Suzuki M, et al.: Apoptosis is a major mode of cell death caused by ischaemia and ischaemia/reperfusion injury to the rat intestinal epithelium. Gut 42:530-537, 1998.
136. Chiu CJ, McArdle AH, Brown R, et al.: Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 101:478-483, 1970.
137. Brunkhorst FM, Clark AL, Forycki ZF, et al.: Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol 72:3-10, 1999.
138. Lemaire LC, van Wagensveld BA, van Gulik TM, et al.: Bacterial translocation to the thoracic duct in a setting of ischemia, partial resection and reperfusion of the porcine liver. Dig Surg 16:222-228, 1999.
139. Dowdall JF, Winter DC, Bouchier-Hayes DJ: Inosine modulates gut barrier dysfunction and end organ damage in a model of ischemia-reperfusion injury. J Surg Res 108:61-68, 2002.
140. Bolke E, Jehle PM, Graf M, et al.: Inflammatory response during abdominal and thyroid surgery: a prospective clinical trial on mediator release. Shock 16:334-339, 2001.
141. Peschel T, Schonauer M, Thiele H, et al.: Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 5:609-614, 2003.
142. Lequier LL, Nikaidoh H, Leonard SR, et al.: Preoperative and postoperative endotoxemia in children with congenital heart disease. Chest 117:1706-1712, 2000.
143. Kumar A, Bunnell E, Lynn M, et al.: Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid a analogue E5531. Chest 126:860-867, 2004.
144. Elin RJ, Wolff SM, McAdam KP, et al.: Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis 144:329-336, 1981.
145. Suffredini AF, Fromm RE, Parker MM, et al.: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321:280-287, 1989.
146. Greenman RL, Schein RM, Martin MA, et al.: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266:1097-1102, 1991.
147. Bone RC: Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 6:57-68, 1993.
148. Cross AS, Opal SM, Bhattacharjee AK, et al.: Immunotherapy of sepsis: flawed concept or faulty implementation? Vaccine 17(suppl 2):13-21, 1999.
149. Norrby-Teglund A, Ihendyane N, Darenberg J: Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis 35:683-689, 2003.
150. Goldie AS, Fearon KC, Ross JA, et al.: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 274:172-177, 1995.
151. Wakefield CH, Barclay GR, Fearon KC, et al.: Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis. Scottish Sepsis Intervention Group. Br J Surg 85:818-825, 1998.
152. Strutz F, Heller G, Krasemann K, et al.: Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome. Intensive Care Med 25:435-444, 1999.
153. Bennett-Guerrero E, Panah MH, Barclay GR, et al.: Decreased endotoxin immunity is associated with greater mortality and/or prolonged hospitalization after surgery. Anesthesiology 94:992-998, 2001.
154. Rothenburger M, Soeparwata R, Deng MC, et al.: The impact of antiendotoxin core antibodies on endotoxin and cytokine release and ventilation time after cardiac surgery. J Am Coll Cardiol 38:124-130, 2001.
155. Mashimo J, Mizutani T, Mita A, et al.: Neutralization of Shwartzman-inducing activity by antibodies recognizing the Re core or lipid A structures of lipopolysaccharide from Salmonella minnesota R595 and Pseudomonas vesicularis JCM1477. Microbiol Immunol 35:423-434, 1991.
156. Warren HS, Amato SF, Fitting C, et al.: Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 177:89-97, 1993.
157. Baumgartner JD, Heumann D, Gerain J, et al.: Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med 171:889-896, 1990.
158. Marra MN, Thornton MB, Snable JL, et al.: Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med 22:559-565, 1994.
159. Baumgartner JD, Heumann D, Glauser MP: The HA-1A monoclonal antibody for gram-negative sepsis. N Engl J Med 325:281, 1991. [Letter to editor].
160. Bhat NM, Bieber MM, Chapman CJ, et al.: Human antilipid A monoclonal antibodies bind to human B cells and the i antigen on cord red blood cells. J Immunol 151:5011-5021, 1993.
161. Helmerhorst EJ, Maaskant JJ, Appelmelk BJ: Anti-lipid A monoclonal antibody centoxin (HA-1A) binds to a wide variety of hydrophobic ligands. Infect Immun 66:870-873, 1998.
162. Quezado ZM, Natanson C, Alling DW, et al.: A controlled trial of HA-1A in a canine model of gram-negative septic shock. JAMA 269:2221-2227, 1993.
163. Charalambous BM, Evans J, Feavers IM, et al.: Comparative analysis of two meningococcal immunotyping monoclonal antibodies by resonant mirror biosensor and antibody gene sequencing. Clin Diagn Lab Immunol 6:838-843, 1999.
164. Suker J, Charalambous BM: Applications of optical biosensor techniques to the characterisation of PortA antibody binding kinetics. In: Pollock DA, Maiden MCJ (eds.): Methods in Molecular Medicine: Meningococcal Vaccines Methods and Protocols. Totowa, NJ: Humana Press, pp 129-143, 2002.
165. Jiang Z, Hong Z, Guo W, et al.: A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo. Int Immunopharmacol 4:527-537, 2004.
166. Dankesreiter S, Hoess A, Schneider-Mergener J, et al.: Synthetic endotoxin-binding peptides block endotoxin-triggered TNF-alpha production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J Immunol 164:4804-4811, 2000.
167. Ciornei CD, Egesten A, Engstrom M, et al.: Bactericidal/permeability- increasing protein inhibits endotoxin-induced vascular nitric oxide synthesis. Acta Anaesthesiol Scand46:1111-1118, 2002.
168. Levy O: Therapeutic potential of the bactericidal/permeability-increasing protein. Expert Opin Investig Drugs 11:159-167, 2002.
169. Estabrook M, Baker CJ, Griffiss JM: The immune response of children to meningococcal lipooligosaccharides during disseminated disease is directed towards primarily against two monoclonal antibody-defined epitopes. J Infect Dis 167:966-970, 1993.
170. Griffiss JM, Brandt BL, Broud DD, et al.: Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis 150:71-79, 1984.
171. Ziegler EJ, McCutchan JA, Fierer J, et al.: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225-1230, 1982.
172. Kirkland TN, Ziegler EJ: An immunoprotective monoclonal antibody to lipopolysaccharide. J Immunol 132:2590-2592, 1984.
173. Bennett-Guerrero E, McIntosh TJ, Barclay GR, et al.: Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine. Infect Immun 68:6202-6208, 2000.
174. Cross AS, Opal SM, Palardy JE, et al.: Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21:4576-4587, 2003.
175. Passwell JH, Ashkenazi S, Harlev E, et al.: Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr Infect Dis J 22:701-706, 2003.
176. Fries LF, Montemarano AD, Mallett CP, et al.: Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun 69:4545-4553, 2001.
177. Kang HY, Curtiss R III: Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization. FEMS Immunol Med Microbiol 37:99-104, 2003.
178. Eko FO, Mayr UB, Attridge SR, et al.: Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J Biotechnol 83:115-123, 2000.
179. Pier GB: Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen. Carbohydr Res 338:2549-2556, 2003.
180. Ryu HI, Kim CJ: Immunologic reactivity of a lipopolysaccharide-protein complex of type A Pasteurella multocida in mice. J Vet Sci 1:87-95, 2000.
181. Estein SM, Cassataro J, Vizcaino N, et al.: The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice. Microbes Infect 5:85-93, 2003.
182. Conlan JW, Shen H, Webb A, et al.: Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20:3465-3471, 2002.
183. Mandrell RE, McLaughlin R, Aba Kwaik Y, et al.: Lipooligosaccharides (LOS) of some Haemophilus species mimic human glycosphingolipids, and some LOS are sialylated. Infect Immun 60:1322-1328, 1992.
184. Moran AP, Prendergast MM, Appelmelk BJ: Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. FEMS Immunol Med Microbiol 16:105-115, 1996.
185. Charalambous BM, Feavers IM: Mimotope vaccines. J Med Microbiol 50:937-939, 2001.
186. Brett PJ, Tiwana H, Feavers IM, et al.: Characterisation of oligopeptides that cross-react with carbohydrate specific antibodies by real-time kinetic, insolution competition ELISA and immunological analyses. J Biol Chem 277:20468-20476, 2002.
187. Winter G, Milstein C: Man-made antibodies. Nature 349:293-299, 1991.